The H1 performance was largely pre-flagged and illustrates how the business is beginning to scale. Revenues increased fourfold to £7.7m, with both Covid and non-Covid related activities contributing to growth. Whilst there is further growth required to hit our FY21 estimates, the company points to an active pipeline of late stage contract opportunities, particularly for international sales of its AbC-19 rapid antibody test. The timing of these is somewhat uncertain, but we make no changes to our ....
09 Mar 2021
Interims in line, waiting for orders to land
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Interims in line, waiting for orders to land
Abingdon Health PLC (ABDX:LON) | 9.2 0 0.0% | Mkt Cap: 11.3m
- Published:
09 Mar 2021 -
Author:
Chris Glasper -
Pages:
3
The H1 performance was largely pre-flagged and illustrates how the business is beginning to scale. Revenues increased fourfold to £7.7m, with both Covid and non-Covid related activities contributing to growth. Whilst there is further growth required to hit our FY21 estimates, the company points to an active pipeline of late stage contract opportunities, particularly for international sales of its AbC-19 rapid antibody test. The timing of these is somewhat uncertain, but we make no changes to our ....